PGEN earnings: real EPS beat/miss history, analyst consensus Buy, P/E -4.15. Updated 2026-07-23.
Precigen (PGEN) Research Hub
Precigen (PGEN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.85 USD (+0.74%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.15, market cap 1.58B. This hub links to the full technical, earnings and options research available for PGEN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.85 USD (+0.74%) |
| 52-week range | 4.43 USD – 7.72 USD |
| Trend regime | Range |
| 14-day RSI | 43.4 (Bearish) |
| Trailing P/E | -4.15 |
| Market cap | 1.58B |
| Dividend yield | 0.00% |
Available research for PGEN
Covered Call on PGEN: how it works, illustrative setup around the real 6.85 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PGEN: how it works, illustrative setup around the real 6.85 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PGEN: how it works, illustrative setup around the real 6.85 USD price, max profit/loss, breakeven and when to use it. Educational.
PGEN technical analysis: range, last 6.85 USD, RSI 43.4, 52w range 4.43 USD–7.72 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PGEN in?
Precigen (PGEN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PGEN in an uptrend or downtrend?
As of 2026-09-11, PGEN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PGEN's trailing P/E ratio?
PGEN's trailing P/E is -4.15, with a market cap of 1.58B. See the earnings research page for full valuation detail.